AstraZeneca PLC (AZN)
75.03
+3.83
(+5.38%)
USD |
NASDAQ |
Apr 25, 16:00
74.26
-0.77
(-1.03%)
After-Hours: 20:00
AstraZeneca Revenue (Quarterly): 12.02B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.02B |
| September 30, 2023 | 11.49B |
| June 30, 2023 | 11.42B |
| March 31, 2023 | 10.88B |
| December 31, 2022 | 11.21B |
| September 30, 2022 | 10.98B |
| June 30, 2022 | 10.77B |
| March 31, 2022 | 11.39B |
| December 31, 2021 | 12.01B |
| September 30, 2021 | 9.866B |
| June 30, 2021 | 8.22B |
| March 31, 2021 | 7.32B |
| December 31, 2020 | 7.41B |
| September 30, 2020 | 6.578B |
| June 30, 2020 | 6.275B |
| March 31, 2020 | 6.354B |
| December 31, 2019 | 6.664B |
| September 30, 2019 | 6.406B |
| June 30, 2019 | 5.823B |
| March 31, 2019 | 5.491B |
| December 31, 2018 | 6.417B |
| September 30, 2018 | 5.34B |
| June 30, 2018 | 5.155B |
| March 31, 2018 | 5.178B |
| December 31, 2017 | 5.777B |
| Date | Value |
|---|---|
| September 30, 2017 | 6.232B |
| June 30, 2017 | 5.051B |
| March 31, 2017 | 5.405B |
| December 31, 2016 | 5.585B |
| September 30, 2016 | 5.699B |
| June 30, 2016 | 5.603B |
| March 31, 2016 | 6.115B |
| December 31, 2015 | 6.399B |
| September 30, 2015 | 5.945B |
| June 30, 2015 | 6.307B |
| March 31, 2015 | 6.057B |
| December 31, 2014 | 6.716B |
| September 30, 2014 | 6.609B |
| June 30, 2014 | 6.762B |
| March 31, 2014 | 6.46B |
| December 31, 2013 | 6.939B |
| September 30, 2013 | 6.25B |
| June 30, 2013 | 6.232B |
| March 31, 2013 | 6.385B |
| December 31, 2012 | 7.282B |
| September 30, 2012 | 6.682B |
| June 30, 2012 | 6.66B |
| March 31, 2012 | 7.349B |
| December 31, 2011 | 8.656B |
| September 30, 2011 | 8.213B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.823B
Minimum
Jun 2019
12.02B
Maximum
Dec 2023
9.110B
Average
9.866B
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| GSK PLC | 10.00B |
| Amgen Inc | 8.196B |
| Sanofi SA | 13.14B |
| Viking Therapeutics Inc | -- |
| Fusion Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 960.00M |
| Total Expenses (Quarterly) | 10.02B |
| EPS Diluted (Quarterly) | 0.31 |
| Enterprise Value | 254.28B |
| Gross Profit Margin (Quarterly) | 80.81% |
| Profit Margin (Quarterly) | 7.98% |
| Earnings Yield | 2.55% |
| Operating Earnings Yield | 3.72% |
| Normalized Earnings Yield | 2.721 |